Impact of obesity on clinical outcomes in patients treated with ceftobiprole: results from Phase 3 clinical trials
This analysis further supports the efficacy and safety of ceftobiprole at current recommended doses in obese patients with SAB, ABSSSI or CABP.
Authors
- Daniel Ionescu
- Andrew F. Shorr (ORCID: https://orcid.org/0000-0002-4537-8328)
- Marc Frederick Engelhardt (ORCID: https://orcid.org/0000-0003-2432-0212)
- Vance G. Fowler (ORCID: https://orcid.org/0000-0002-8048-0897)
- Mikael Saulay
- Thomas L Holland (ORCID: https://orcid.org/0000-0001-7745-9010)
- Karine Litherland (ORCID: https://orcid.org/0009-0000-8243-0482)
- Mark E. Jones
- J. Scott Overcash
Institutions
- MedStar Washington Hospital Center (US)
- Duke University (US)
- Clinical Research Institute (US)
- Velocity Clinical Research (United States) (US)
- Basilea Pharmaceutica (Switzerland) (CH)
Publication Details
- Journal
- Journal of Antimicrobial Chemotherapy
- Published
- 2025-03-28
- DOI
- https://doi.org/10.1093/jac/dkaf096
- Primary Topic
- Antimicrobial Resistance in Staphylococcus
- Type
- article
- Field-Weighted Citation Impact
- 0.00